AstraZeneca Results Presentation Deck
Core operating profit mix and full-year 2021 guidance
Continued improvement in the core operating mix
Core operating profit mix
$m
2,750
2,500
2,250
2,000
1,750
1,500
1,250
1,000
750
500
250
0
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Residual Collaboration Revenue Core Other Operating Income
Q2 2021
Q3 2021
Full-year 2021 guidance¹ (CER)
Total Revenue
Increase by a low-twenties percentage
excluding COVID-19 vaccine
Increase by a mid-to-high twenties percentage
including Q4 COVID-19 vaccine sales
Growth to $5.05 to $5.40
Core EPS
1. Prior guidance excluded the revenue and profit impact of sales of the pandemic vaccine. COVID-19 vaccine sales in Q4 2021 are expected to be a blend of the original pandemic agreements and new commercial contracts. The
12 contribution from the vaccine in Q4 2021 is expected to offset investment in R&D and supporting activities for the COVID-19 medicines (the vaccine and AZD7442), resulting in no change to Core EPS guidance. The calculation of
Core EPS for guidance is based on 1,418 million weighted average number of shares outstanding during 2021. The number of shares in issue as of the close of the Alexion acquisition was 1,549 million.
BView entire presentation